We are obviously disappointed with this turn of events, but we are still heartened that the first jury to hear an Actos claim found for the plaintiff. We remain optimistic that future Actos bladder cancer lawsuits will yield victories for plaintiffs.
New York, New York (PRWEB) May 03, 2013
The Actos lawyers at Bernstein Liebhard LLP note that a California Superior Court judge has set aside a $6.5 million verdict handed down last week in the nation’s first Actos bladder cancer trial. According to a May 3rd Reuters report, in granting Takeda Pharmaceuticals' request to nullify the verdict, Judge Kenneth Freeman of Los Angeles Superior Court asserted that the Plaintiff’s medical expert had failed to establish that Actos was the specific cause of Cooper's bladder cancer.* (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
“We are obviously disappointed with this turn of events, but we are still heartened that the first jury to hear an Actos claim found for the plaintiff. We remain optimistic that future Actos bladder cancer lawsuits will yield victories for plaintiffs,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to long-term users of the medication who have been diagnosed with bladder cancer.
Actos Bladder Cancer Lawsuits
Court records indicate that Takeda has been named in more than 3,000 Actos bladder cancer lawsuits. Some 1,200 of those Actos lawsuits have been filed in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. The first trial in that litigation is expected to begin next January. (In re: Actos Product Liability Litigation, MDL No. 2299) All of the Actos lawsuits allege Takeda knew that Actos could increase the risk of bladder cancer in patients taking the drug, but failed to provide adequate warnings about this increased risk.
According to court documents, the Plaintiff in the Los Angeles Actos bladder cancer trial had taken the drug for four years before being diagnosed with the disease. According to an April 15th Bloomberg.com story, evidence introduced at trial included internal Takeda emails that suggested company officials were worried about the impact an Actos bladder cancer warning would have on sales of the drug. The Plaintiff’s attorneys also told the jury that Takeda had known about the connection between Actos and bladder cancer since 2004, but did not inform regulators for 7 years.**
The litigation surrounding Actos has been growing since June 2011, when the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use increased the risk for bladder cancer.*** According to a February 28th Bloomberg.com report, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.****
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call (877) 779-1414 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP